Avatrombopag Medication Guide: Who should use it, how to use it, and how much it costs?

Research on perioperative and chronic thrombocytopenia (thrombocytopenia) management has continued to be active in recent years. With the development of precision medicine and oral small molecule drugs, avatrombopag (trade name DOPTELET etc.), as an oral thrombopoietin receptor agonist (TPO-RA), has shown obvious advantages in increasing preoperative platelets and reducing the need for platelet transfusion; at the same time, in specific countries/ region are also constantly expanding, including the approval of chronic primary immune thrombocytopenia (ITP) and research progress in pediatric populations, which has attracted great attention from clinical and patient groups.

1. Why does avatrombopag attract so much attention?

Avatrombopag (Avatrombopag), as an oral thrombopoietin receptor agonist (TPO-RA), has quickly attracted widespread attention from clinicians and patients because of its convenient administration and significant platelet-raising effect. Especially in patients with chronic liver disease-related thrombocytopenia, it can effectively increase platelet levels in the short term before surgery, thereby reducing the need for platelet transfusions and improving perioperative safety.

In addition to perioperative applications, avatrombopag has also made progress in the application of chronic immune thrombocytopenia (ITP) and children, and its indications continue to expand. With its domestic launch and medical insurance coverage, patient accessibility and economic burden issues have also been significantly improved, making it gradually become one of the important drugs for the management of thrombocytopenia.

2. Drug introduction and mechanism of action

Avatrombopag is an oral small molecule thrombopoietin receptor agonist. By binding to the TPO receptor (MPL), it simulates the effect of thrombopoietin (TPO) in the human body and stimulates megakaryocytes in the bone marrow to produce and release platelets. Unlike traditional platelet transfusion, it increases platelet levels by activating the body's own hematopoietic function, with a longer-lasting effect and lower risks.

With otherTPO-RA (such asEltrombopag,Romiplostim) A characteristic of avatrombopag is that it does not need to be taken on an empty stomach and is not likely to interact with polyvalent cations in food. It is convenient to take and helps improve patient compliance.

3. Indications and approval progress globally and in China

In 2018, the United StatesFDA approved avatrombopag for the treatment of adult patients with thrombocytopenia associated with chronic liver disease who are scheduled to undergo elective surgery. Short-term oral administration (5days) can significantly increase platelet levels before surgery and reduce the risk of platelet transfusion. This is its first and most influential indication.

Subsequently, the role of avatrombopag in the treatment of chronic ITP was gradually recognized. Clinical studies have shown that it can help increase and maintain platelet levels and reduce the risk of bleeding in ITP patients who have insufficient response to hormone or immunoglobulin therapy. Some countries and regions have approved its indications for ITP. In recent years, its clinical research and registration in the field of children's ITP have also made progress.

In China, avatrombopag has been officially launched and included in the medical insurance catalog. In China, it is mainly used for patients with perioperative thrombocytopenia and ITP.

4. Clinical research evidence

The efficacy and safety of avatrombopag have been confirmed through multiple international large-scaleIII phase clinical studies. ADAPT-1 and ADAPT-2 Studies have shown that in patients with chronic liver disease-related thrombocytopenia, avatrombopag can effectively increase platelet counts before surgery, significantly reduce the need for platelet transfusions, and reduce the risk of bleeding.

In the ITP field, multiple randomized controlled trials and real-world studies have shown that avatrombopag can significantly improve platelet levels in patients with poor response to previous treatments. Some patients can still maintain high platelet values u200bu200bafter stopping the drug, showing good sustained efficacy. Studies in pediatric populations also suggest that it is effective and safe.

5. Usage, dosage and precautions

In perioperative short-term treatment, the common usage is to start taking medicine 10 to 13 days before surgery and continue to take it orally5 days, and the surgery is scheduled to be performed within 5 to 8 days after the last dose. Dosage is determined based on baseline platelet levels:

- Baseline <40×10⁹/L: Daily60 mg, continuous5 days;

- Baseline 40–<50×10⁹/L: Daily40 mg for 5 consecutive days.

In chronic ITPtreatment, a common starting dose is 20 mg once daily, with the dose adjusted based on platelet response to maintain target levels. Dosage for children needs to be based on body weight and specific instructions.

The platelet count needs to be monitored regularly during medication to avoid raising the platelet count too high to avoid increasing the risk of blood clots.

6. Adverse reactions and safety

Avatrombopag is generally well tolerated, and common adverse reactions include gastrointestinal discomfort (nausea, abdominal pain, diarrhea), headache, fatigue, etc. Individual patients may experience thrombotic events, especially those with high-risk factors. Therefore, the risk of thrombosis should be assessed before use and close monitoring is required during use.

Different from otherTPO-RA, avatrombopag is not likely to cause hepatotoxicity and does not require regular monitoring of liver function. It is relatively more friendly to patients with chronic liver disease, but it still needs to be used with caution according to the condition.

7. Price information and medical insurance policy

At present, avatrombopag has been launched in the country and is included in medical insurance. Common specifications and prices are as follows:

- 20mg

- 20mg

The specific medical insurance reimbursement amount varies depending on regional policies. Patients are advised to consult the local hospital pharmacy.

In the international market, generic drugs such as the Lao version and the Bangladeshi version have been launched. Their ingredients are basically the same as the original drugs and the price is only a few hundred yuan. However, it is necessary to ensure that the drug purchase channels are formal and safe.

8. Clinical Application Suggestions

For perioperative patients with chronic liver disease-related thrombocytopenia, avatrombopag provides a safe, effective and convenient option for short-term platelet elevation. It provides new treatment options for patients with chronic ITP, especially those who are unresponsive to hormones or immunoglobulins.

When using this drug, patients should strictly follow the doctor's advice, regularly monitor platelet levels, pay attention to the risk of thrombosis, purchase drugs through regular hospital pharmacies, enjoy medical insurance policies, and avoid purchasing generic drugs through informal channels.

With the accumulation of real-world data and the expansion of indications, avatrombopag has broad application prospects in ITP and children. In the future, more research will further explore its long-term safety, economic benefits and application value in different clinical scenarios.

xa0

References:

1. FDA DOPTELET (avatrombopag) approval information

2. ADAPT-1/ADAPT-2 Clinical trial results

3. China State Food and Drug Administration and Medical Insurance Catalog Information

4. Recent Real World Research and ChildrenITPRegistration Information